Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Main billing specialties: neurosurgery and interventional radiology.
Medicare fee-for-service aneurysm & intracranial embolization cases in the 33 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 48 | 1,774+17%/yr | +17%/yr | 0.51.1× | 0% | 3,530 in 2030+12%/yr |
| Florida | 40 | 1,299+18%/yr | +18%/yr | 0.61.2× | 0% | 2,280 in 2030+9.8%/yr |
| New York | 25 | 1,148+12%/yr | +12%/yr | 0.61.3× | 0% | 1,980 in 2030+9.5%/yr |
| Texas | 28 | 1,099+13%/yr | +13%/yr | 0.51.1× | 0% | 2,130 in 2030+12%/yr |
| Pennsylvania | 29 | 803+20%/yr | +20%/yr | 0.61.2× | 0% | 1,470 in 2030+11%/yr |
| Illinois | 17 | 594+15%/yr | +15%/yr | 0.40.9× | 0% | 1,210 in 2030+13%/yr |
| Ohio | 15 | 485+7.7%/yr | +7.7%/yr | 0.40.9× | 0% | 720 in 2030+6.9%/yr |
| Massachusetts | 13 | 456+8%/yr | +8%/yr | 0.51.0× | 0% | 820 in 2030+10%/yr |
| Virginia | 11 | 407+13%/yr | +13%/yr | 0.40.8× | 0% | 670 in 2030+8.8%/yr |
| New Jersey | 13 | 399+11%/yr | +11%/yr | 0.40.8× | 0% | 600 in 2030+7.1%/yr |
| Washington | 12 | 398+16%/yr | +16%/yr | 0.51.1× | 0% | 840 in 2030+13%/yr |
| Michigan | 7 | 386+9.3%/yr | +9.3%/yr | 0.51.0× | 0% | 640 in 2030+8.7%/yr |
| North Carolina | 13 | 383+6.3%/yr | +6.3%/yr | 0.40.8× | 0% | 640 in 2030+8.8%/yr |
| Arizona | 12 | 342+14%/yr | +14%/yr | 0.51.0× | 0% | 770 in 2030+14%/yr |
| Tennessee | 9 | 328+6.6%/yr | +6.6%/yr | 0.51.0× | 0% | 490 in 2030+6.8%/yr |
| Maryland | 10 | 326+15%/yr | +15%/yr | 0.40.8× | 0% | 570 in 2030+9.9%/yr |
| Georgia | 8 | 323+8.8%/yr | +8.8%/yr | 0.40.8× | 0% | 940 in 2030+19%/yr |
| Missouri | 6 | 309+17%/yr | +17%/yr | 0.51.0× | 0% | 370 in 2030+2.8%/yr |
| Minnesota | 8 | 304+10%/yr | +10%/yr | 0.71.4× | 0% | 720 in 2030+16%/yr |
| Kentucky | 9 | 226+16%/yr | +16%/yr | 0.51.0× | 0% | 310 in 2030+5.4%/yr |
| Colorado | 6 | 214+15%/yr | +15%/yr | 0.40.9× | 0% | 430 in 2030+12%/yr |
| Connecticut | 6 | 214+31%/yr | +31%/yr | 0.61.4× | 0% | 330 in 2030+7.6%/yr |
| Indiana | 8 | 202+15%/yr | +15%/yr | 0.30.6× | 0% | 430 in 2030+13%/yr |
| Alabama | 6 | 196+34%/yr | +34%/yr | 0.40.9× | 0% | 300 in 2030+7.4%/yr |
| South Carolina | 9 | 195−0.2%/yr | −0.2%/yr | 0.30.6× | 0% | 440 in 2030+15%/yr |
| Nevada | 3 | 177+15%/yr | +15%/yr | 0.61.3× | 0% | 310 in 2030+9.8%/yr |
| Iowa | 5 | 166+11%/yr | +11%/yr | 0.40.8× | 0% | 360 in 2030+14%/yr |
| Oklahoma | 2 | 164+3.5%/yr | +3.5%/yr | 0.30.7× | 0% | 450 in 2030+18%/yr |
| Louisiana | 7 | 162+8.9%/yr | +8.9%/yr | 0.40.8× | 0% | 220 in 2030+5%/yr |
| Wisconsin | 2 | 154+1.5%/yr | +1.5%/yr | 0.30.6× | 0% | 470 in 2030+20%/yr |
| Kansas | 5 | 146+15%/yr | +15%/yr | 0.40.8× | 0% | 210 in 2030+6.6%/yr |
| Mississippi | 4 | 119+13%/yr | +13%/yr | 0.30.7× | 0% | 110 in 2030−1.2%/yr |
| Oregon | 2 | 108+11%/yr | +11%/yr | 0.30.5× | 0% | 150 in 2030+5.8%/yr |
Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 126 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 13 companies. The most active:
Product codes: HCG (device, neurovascular embolization), KGG (tissue adhesive for use in embolization of brain arteriovenous malformations), NPE (material, embolization, neurovascular, polymerizing or precipitating), OUT (intracranial aneurysm flow diverter). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 37% of the cases CMS names in California; 33 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Stroke thrombectomy | 446 | 12,543+1.7%/yr | +1.7%/yr | 14,600 in 2030+2.5%/yr |
| DBS & VNS | 156 | 9,717−3.7%/yr | −3.7%/yr | 14,000 in 2030+6.2%/yr |
| CSF shunts | 56 | 5,163−4.8%/yr | −4.8%/yr | 6,290 in 2030+3.3%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 14 companies reported engagement with surgeons in the covered states worth $7.8M in consulting, speaking, meals and travel tied to these products, about $20K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.